Alteration of PPAR‐GAMMA (PPARG; PPARγ) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPARγ stimulation using pioglitazone on AML cells

Molecular Genetics & Genomic Medicine

Davood Bashash¹  Shadi Esmaeili¹  Vahid Kaveh²  Sina Salari³  Seyed H. Ghaffari⁴ 

[1] Department of Hematology and Blood Banking School of Allied Medical Sciences Shahid Beheshti University of Medical Sciences Tehran Iran;Department of Medical Oncology and Hematology Iran University of Medical Sciences Tehran Iran;Department of Medical Oncology, Hematology and Bone Marrow Transplantation Taleghani HospitalShahid Beheshti University of Medical Sciences Tehran Iran;Hematology, Oncology and Stem Cell Transplantation Research Center Shariati HospitalSchool of MedicineTehran University of Medical Sciences Tehran Iran;

关键词: acute myeloid leukemia;    peroxisome proliferator‐activated receptor‐γ;    pioglitazone;    PPARγ;    PTEN;   

DOI  :  10.1002/mgg3.1818

来源: DOAJ

【 摘 要 】

Abstract Background In the new era of tailored cancer treatment strategies, finding a molecule to regulate a wide range of intracellular functions is valuable. The unique property of nuclear receptor peroxisome proliferator‐activated receptor‐γ (PPARγ; PPARG) in transmitting the anti‐survival signals of the chemotherapeutic drugs has fired the enthusiasm into the application of this receptor in cancer treatment. Objectives We aimed to investigate the expression of PPARγ and one of its downstream targets PTEN in non‐M3 acute myeloid leukemia (AML) patients. We also investigated the therapeutic value of PPARγ stimulation using pioglitazone in the AML‐derived U937 cell line. Methods The blood samples from 30 patients diagnosed with non‐M3 AML as well as 10 healthy individuals were collected and the mRNA expression levels of PPARγ and PTEN were evaluated. Additionally, we used trypan blue assay, MTT assay, and flow cytometry analysis to evaluate the anti‐leukemic effects of pioglitazone on U937 cells. Results While PTEN was significantly downregulated in AML patients as compared to the control group, the expression of PPARγ was increased in the patients’ group. The expression level of PPARγ was also negatively correlated with PTEN; however, it was not statistically significant. Besides, PPARγ stimulation using pioglitazone reduced survival and proliferative capacity of U937 cells through inducing apoptosis and suppression of cell transition from the G1 phase of the cell cycle. Conclusion The results of the present study shed more light on the importance of PPARγ and its stimulation in the therapeutic strategies of AML.

【 授权许可】

Unknown